Development and Biological Properties of a New Live Attenuated Mumps Vaccine Strain
Xue Song1, Xiumei Ren1, Yang Song1
1Beijing Minhai Biotechnology Co., Ltd., Beijing 102609, China.
Abstract:
Background/Objectives: This study aimed to develop a new attenuated live mumps vaccine strain and determine its biological properties and effectiveness. Methods: Plaque purification and amplification were performed in chicken embryo cells. Candidate live attenuated mumps MuV-365 strain sequencing was performed. After evaluating the potential neurotoxicity of the MuV-365 mumps strain, a preclinical safety evaluation of measles-mumps-rubella (MMR) live attenuated vaccine containing the MuV-365 strain was performed to support the registration and application of the MMR vaccine. Finally, mumps neutralization antibody titers and the concentration of anti-serum mumps-specific IgG were determined to evaluate the immunogenicity and efficacy of the MuV-365 strain and MMR vaccine in mice and rhesus monkeys. Results: The plaque of the PL-KUM main seed virus was screened, and strains whose sequences were highly homologous to RIT4385 (JL-5 derived) were selected to amplify. The candidate live attenuated mumps MuV-365 strain was then developed. Safety evaluation results indicated that the MuV-365 strain had no potential neurotoxicity, and the MMR vaccine containing the MuV-365 strain also showed no significant safety hazard. The immunogenicity of MuV-365 strain in BALB/c mice was not inferior to S79 and PL-KUM. After two doses of the MuV-365 strain, the concentration of anti-serum mumps-specific IgG of the MuV-365 strain was significantly higher than that of the S79 strain (p < 0.01). In rhesus monkeys, the MMR vaccine had good immunogenicity against measles and rubella after one dose, while immunogenicity against mumps improved after two doses. Conclusions: The developed MuV-365 strain was genetically stable, with adequate safety and immunogenicity.
Insights
A new live attenuated mumps vaccine strain, MuV-365, was developed and demonstrated safety and efficacy. This promising mumps vaccine candidate shows genetic stability and strong immunogenicity in preclinical studies.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- Development of novel vaccine strains is crucial for controlling infectious diseases.
- Mumps remains a public health concern, necessitating effective vaccination strategies.
Purpose of the Study:
- To develop and characterize a new live attenuated mumps vaccine strain (MuV-365).
- To evaluate the safety, immunogenicity, and efficacy of the MuV-365 strain and a measles-mumps-rubella (MMR) vaccine containing it.
Main Methods:
- Plaque purification, amplification, and sequencing of the candidate MuV-365 strain.
- Preclinical safety evaluation for neurotoxicity and general vaccine safety.
- Immunogenicity and efficacy assessment in mice and rhesus monkeys via antibody titer determination.
Main Results:
- The MuV-365 strain was successfully developed and showed high sequence homology to established strains.
- No neurotoxicity was observed for MuV-365; the MMR vaccine containing it demonstrated a good safety profile.
- MuV-365 exhibited comparable or superior immunogenicity to existing strains in mice and induced robust antibody responses in rhesus monkeys.
Conclusions:
- The MuV-365 strain is genetically stable, safe, and immunogenic.
- This novel mumps vaccine candidate holds potential for effective mumps prevention.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:51Vaccinations